Thrombin Generation in Liver Transplant Surgery

Status Recruiting

Clinical Trial Summary

This is a prospective observational study of 100 patients undergoing liver transplantation at a single centre. Thrombin generation and kinetics will be assessed using a novel point-of-care device, and compared to conventional measures of hemostasis as well as viscoelastic tests to pinpoint specific coagulation deficits and identify potential therapeutic targets. The clinical course of patients will be followed for major bleeding and transfusion outcomes.

Clinical Trial Description

Liver transplantation is the only curative option for end stage liver disease, but is associated with high morbidity and mortality. End stage liver disease is known to be accompanied by dysregulated coagulation, which is further exacerbated in the immediate perioperative period by transplantation, leading to both coagulopathic bleeding and thrombosis. Altered thrombin generation is thought to play a key role in the predisposition of these patients for both severe coagulopathic hemorrhage and life-threatening thromboembolic complications. Despite this, thrombin generation during the immediate transplant period in patients with end-stage liver disease is poorly characterized, in part because it is not well reflected by conventional measures of coagulation. This study aims to characterize changes in thrombin generation capacity pre, intra- and post-transplant utilizing a novel point-of-care thrombin generation assay. Other specific aims of the study are to identify risk factors for patients with impaired thrombin generation and will assess the association of impaired thrombin generation with overall clinical bleeding risk. The overarching goal of this work is to develop a point-of-care-testing guided algorithm addressing dysregulated thrombin formation that improves coagulation management without increasing the risk of thromboembolic complications. Ultimately, this line of research will improve the outcomes of liver transplantation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04762550
Study type	Observational
Source	University Health Network, Toronto
Contact	Justyna Bartoszko, MD MSc FRCPC
Phone	416-340-4800
Email	justyna.bartoszko@uhn.ca
Status	Recruiting
Phase
Start date	March 8, 2021
Completion date	January 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04180735` - Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
Completed	`NCT01011205` - Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation	Phase 3
Completed	`NCT01888432` - Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants	Phase 3
Recruiting	`NCT04203004` - HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)	N/A
Recruiting	`NCT04564313` - Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation	Phase 1
Withdrawn	`NCT03596970` - Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.	Phase 3
Not yet recruiting	`NCT02544906` - Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation	N/A
Completed	`NCT03133065` - Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs	Phase 4
Recruiting	`NCT01705015` - Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement	N/A
Completed	`NCT01425385` - Autoregulation Assessment During Liver Transplantation	N/A
Terminated	`NCT01445236` - Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance	N/A
Completed	`NCT01655563` - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation	Phase 2
Completed	`NCT00938860` - Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C	Phase 4
Completed	`NCT00531921` - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival	N/A
Completed	`NCT00456235` - Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors	Phase 4
Withdrawn	`NCT00585429` - Evaluation of Kidney Disease in Liver Transplant Recipients	N/A
Terminated	`NCT00585858` - Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant	N/A
Recruiting	`NCT00147459` - Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation	N/A
Withdrawn	`NCT00167492` - Enteric Coated Myfortic for Liver Transplant Recipients	Phase 4
Terminated	`NCT00161356` - Ambisome in Liver Transplant Patients	Phase 4